Hybrid imaging of benign skeletal diseases

Einat Even-Sapir*, Hedva Lerman, Gideon Flusser, Arye Blachar

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

99mTc-methylene diphosphonate (99mTc-MDP) is the most commonly used bone radiopharmaceutical for scintigraphic assessment of skeletal abnormalities. The compound, an analogue of pyrophosphate, is chemisorbed onto bone surface. Its uptake depends on local blood flow and bone turnover. As little as 5-10% change in lesion to normal bone uptake ratio is required to detect pathology on bone scintigraphy (BS) preceding their detection on plain radiographs or CT by 2-18 months.1 Based on these characteristics, BS with 99mTc-MDP is highly sensitive for the detection of various benign skeletal abnormalities associated with increased bone turnover including trauma, osteomyelitis, osteoporosis, metabolic skeletal disease, degenerative changes, etc.

Original languageEnglish
Title of host publicationHybrid PET/CT and SPECT/CT Imaging
Subtitle of host publicationA Teaching File
PublisherSpringer New York
Pages683-709
Number of pages27
ISBN (Print)9780387928197
DOIs
StatePublished - 2010

Fingerprint

Dive into the research topics of 'Hybrid imaging of benign skeletal diseases'. Together they form a unique fingerprint.

Cite this